Advertisement
UK markets close in 2 hours 47 minutes
  • FTSE 100

    8,219.98
    -27.81 (-0.34%)
     
  • FTSE 250

    20,311.54
    -51.89 (-0.25%)
     
  • AIM

    765.96
    -2.07 (-0.27%)
     
  • GBP/EUR

    1.1841
    +0.0004 (+0.03%)
     
  • GBP/USD

    1.2653
    -0.0034 (-0.27%)
     
  • Bitcoin GBP

    48,485.17
    +184.68 (+0.38%)
     
  • CMC Crypto 200

    1,275.13
    -8.65 (-0.67%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CRUDE OIL

    81.32
    +0.49 (+0.61%)
     
  • GOLD FUTURES

    2,327.70
    -3.10 (-0.13%)
     
  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     
  • HANG SENG

    18,089.93
    +17.03 (+0.09%)
     
  • DAX

    18,105.73
    -71.89 (-0.40%)
     
  • CAC 40

    7,586.55
    -75.75 (-0.99%)
     

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Optinose, Inc.
Optinose, Inc.

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.

To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

A replay of the webcast will be available for 30 days following the conclusion of the event.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531